4 insiders reported 5 Form 4 transactions for Elicio Therapeutics, Inc. (ELTX) over the past 18 months (most recent 2026-02-03). Recent activity: Haqq Christopher (Executive Vice President, Head of R&D and Chief Medical Officer) Buy 25,400 shares, DeMuth Peter (Chief Scientific Officer) Buy 20,800 shares, Shah Preetam (Chief Strategy and Financial Officer) Buy 24,000 shares, Connelly Robert (CEO, President and Director) Buy 73,600 shares, DeMuth Peter (Chief Scientific Officer) Buy 362 shares. Source: SEC Form 4.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-03 | Haqq Christopher | Executive Vice President, Head of R&D and Chief Medical Officer | Buy | 25,400 | $0 |
| 2026-02-03 | DeMuth Peter | Chief Scientific Officer | Buy | 20,800 | $0 |
| 2026-02-03 | Shah Preetam | Chief Strategy and Financial Officer | Buy | 24,000 | $0 |
| 2026-02-03 | Connelly Robert | CEO, President and Director | Buy | 73,600 | $0 |
| 2025-12-10 | DeMuth Peter | Chief Scientific Officer | Buy | 362 | $1,596 |
来源：SEC Form 4 申报文件 · 截至 2026-02-03